AAPG
NASDAQAscentage Pharma Group International
$15.92+0.65 (+4.26%)
Ascentage Pharma Group International (AAPG) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 7 wire items for AAPG, including 4 SEC filings, 2 analyst ratings and 1 offering. The most recent was published Oct 22, 2026.
Price$15.92-2.97 (-15.72%)
2026-07-272026-10-27
News · 26 weeks42+200%
2026-05-032026-10-25
Mix1790d
- SEC Filings9(53%)
- Offering6(35%)
- Analyst2(12%)
Latest news
25 items- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLLROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), in combination with acalabrutinib, for the treatment of treatment-naïve adult patients with chronic lymphocytic leukemia/small lymphocytic ly
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- ANALYSTCitigroup initiated coverage on Ascentage Pharma with a new price targetCitigroup initiated coverage of Ascentage Pharma with a rating of Buy and set a new price target of $46.00
- ANALYSTCitizens initiated coverage on Ascentage Pharma with a new price targetCitizens initiated coverage of Ascentage Pharma with a rating of Mkt Outperform and set a new price target of $35.00
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Participate in Four Upcoming Investor ConferencesROCKVILLE, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in four upcoming investor conferences in New York, New York. Citi’s 2026 Biopharma Back to School ConferenceFormat: Fireside chat and one-on-one investor meetingsDate and Time: Wednesday, September 9, 2026, 4:20 p.m. to 4:55 p.m. ETLocation: JW Marriott Essex House, 160 Central
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business UpdatesRevenue for the first half of 2026 increased 29% year-over-year to US$44.5 million (RMB302.2 million), primarily attributable to increased product sales. Expanded executive leadership with appointments of Dr. Faical Miyara as Chief Business Officer and Mr. James Ziegler as Chief Commercial Officer Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor webcast at 9:00 am HKT on August 20, 2026 / 9:00 pm EDT on August 19, 2026; and English language investor webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026 ROCKVILLE, Md., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Participate in the Evercore 2nd Annual China Biotech SummitROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management will participate in the Evercore ISI 2nd Annual China Biotech Summit, being held August 17-19, 2026 at The Ritz-Carlton Shanghai, Pudong. Management will participate in a fireside chat moderated by the Evercore research team and one-on-one investor meetings during the conference. Fireside C
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026ROCKVILLE, Md., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)) ("Ascentage Pharma" or the "Company"), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that it will release its six months 2026 unaudited interim results and provide business updates at 9:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 9:00 pm Hong Kong Time (HKT) on August 19, 2026. Analysts and investors are invited to join the investor webcast with Q&A, conducted by the Company’s management team. Ascentage Pharma w
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial OfficerROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced the appointment of Faiçal Miyara, PhD, as Chief Business Officer (CBO), responsible for the Company’s global business development, and Jim Ziegler as Chief Commercial Officer (CCO), responsible for the commercialization of the Company’s products in the United States and other countries outside of China. Together, the appointments create a US commercialization function with dedi
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- PRAscentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026ROCKVILLE, Md. and SUZHOU, China, July 26, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ:AAPG, HKEX: 6855)), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that its Chairman and Chief Executive Officer, Dr. Dajun Yang, has been named to The Medicine Maker Power List 2026, ranking No. 3 among the Top 10 in the Small Molecules category. Published annually, the Power List recognizes global leaders across small molecules, biopharma and advanced therapies. Nominated by industry peers worldwide and selected by a panel o
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form F-3ASR filed by Ascentage Pharma Group InternationalF-3ASR - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
- INSIDERSEC Form 3 filed by new insider Miyara Faical3 - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Issuer)
- SECSEC Form 6-K filed by Ascentage Pharma Group International6-K - ASCENTAGE PHARMA GROUP INTERNATIONAL (0002023311) (Filer)
AAPG FAQ
7 questionsWhat is the latest news on AAPG?
In the last 30 days Quantisnow tracked 7 wire items for AAPG: 4 SEC filings, 2 analyst ratings and 1 offering. The most recent was published on October 22, 2026.Where does AAPG stock trade?
Ascentage Pharma Group International (AAPG) is listed on NASDAQ.What sector and industry is AAPG in?
Ascentage Pharma Group International operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ascentage Pharma Group International go public?
Ascentage Pharma Group International (AAPG) completed its IPO in 2025.What are analysts saying about AAPG?
Ascentage Pharma Group International has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $4600.00 price target on 2026-10-14. Recent price targets range from $3500.00 to $4800.00.What companies are similar to AAPG?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AAPG side-by-side with any of them on Quantisnow.How can I track AAPG on Quantisnow?
Quantisnow aggregates Ascentage Pharma Group International's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AAPG to receive live email and push alerts on every new disclosure.